The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2025
Filed:
May. 29, 2019
Applicant:
Glycostem Therapeutics B.v., AB Oss, NL;
Inventors:
Jan Spanholtz, AB Oss, NL;
Nina Kok, AB Oss, NL;
Alessandra Gatti, Milan, IT;
Giuliana Vallanti, Milan, IT;
Catia Traversari, Milan, IT;
Assignee:
GLYCOSTEM THERAPEUTICS B.V., AB Oss, NL;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/0789 (2010.01); C12N 15/86 (2006.01); G01N 33/50 (2006.01); G01N 33/543 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2884 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/421 (2025.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C12N 5/0087 (2013.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01); C12N 15/86 (2013.01); G01N 33/5002 (2013.01); G01N 33/54326 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C12N 2501/125 (2013.01); C12N 2501/145 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/26 (2013.01); C12N 2740/15043 (2013.01);
Abstract
A method of manufacturing of Natural Killer (NK) Cells genetically modified with lentiviral vectors carrying a polynucleotide coding for a Chimeric Antigen Receptors (CARs). CAR-NK cells obtained with the method, and the use of the CAR-NK cells in medicine, in particular for use in a method of treating cancer is also disclosed.